Segment Information

12 Months Ended

Dec. 31, 2019

Segment Reporting [Abstract]

Segment Information

Segment Information

Segment reporting is prepared on the same basis that the Company’s chief executive officer, who is the Company’s chief operating decision maker, manages the business, makes operating decisions and assesses performance. The Company operates in one segment, pharmaceuticals. Enterprise-wide disclosures about revenues, significant customers, and property and equipment, net by location are presented below.

Revenues by Product

Product revenues, net consisted of the following:

	2019 (as reported under ASC 606)		2018 (as reported under ASC 606)		2017 (as reported under ASC 605)
	(in thousands)
TRIKAFTA	$	420,105	$	—	$	—
SYMDEKO/SYMKEVI	1,417,668		768,657		—
ORKAMBI	1,331,891		1,262,166		1,320,850
KALYDECO	991,062		1,007,502		844,630
Total product revenues, net	$	4,160,726	$	3,038,325	$	2,165,480

Revenues by Geographic Location

Net product revenues are attributed to countries based on the location of the customer. Collaborative and royalty revenues are attributed to countries based on the location of the Company’s subsidiary associated with the collaborative arrangement related to such revenues. Total revenues from external customers and collaborators by geographic region consisted of the following:

	2019 (as reported under ASC 606)		2018 (as reported under ASC 606)		2017 (as reported under ASC 605)
	(in thousands)
United States	$	3,062,555	$	2,365,079	$	1,986,786
Outside of the United States
Europe	885,762		543,179		420,317
Other	214,504		139,339		81,549
Total revenues outside of the United States	1,100,266		682,518		501,866
Total revenues	$	4,162,821	$	3,047,597	$	2,488,652

Significant Customers

Gross revenues and accounts receivable from each of the Company’s customers who individually accounted for 10% or more of total gross revenues and/or 10% or more of total gross accounts receivable consisted of the following:

	Percent of Total Gross Revenues						Percent of Gross Accounts Receivable
	Year Ended December 31,						As of December 31,
	2019 (as reported under ASC 606)		2018 (as reported under ASC 606)		2017 (as reported under ASC 605)		2019		2018
McKesson Corporation	17	%	14	%	<10	%	22	%	16	%
Walgreen Co.	15	%	20	%	17	%	14	%	16	%
Accredo/Curascript	14	%	14	%	14	%	15	%	10	%

Long-lived Assets by Location

Long-lived assets by location consisted of the following:

	As of December 31,
	2019		2018
	(in thousands)
United States	$	768,572	$	778,157
Outside of the United States
United Kingdom	57,383		30,496
Other	7,327		3,352
Total long-lived assets outside of the United States	64,710		33,848
Total long-lived assets	$	833,282	$	812,005